Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trial
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trial
Authors
Keywords
-
Journal
Diabetes & Vascular Disease Research
Volume 12, Issue 6, Pages 455-462
Publisher
SAGE Publications
Online
2015-07-30
DOI
10.1177/1479164115579002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
- (2015) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
- (2014) P.-H. Groop et al. DIABETES OBESITY & METABOLISM
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat
- (2014) Ravi Nistala et al. Obesity
- The Landscape of Clinical Trials in Nephrology: A Systematic Review of ClinicalTrials.gov
- (2013) Jula K. Inrig et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1^|^alpha; in type 2 diabetic patients with incipient nephropathy
- (2013) Hiroki Fujita et al. ENDOCRINE JOURNAL
- Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
- (2013) K. Sharma et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
- (2012) Markus L. Alter et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
- (2011) Cristina Mega et al. Experimental Diabetes Research
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
- (2008) J. C. N. Chan et al. DIABETES OBESITY & METABOLISM
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation